Horizon Pharma PLC  

(Public, NASDAQ:HZNP)   Watch this stock  
Find more results for HZNP
13.98
+0.33 (2.42%)
Real-time:   3:00PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.71 - 14.06
52 week 9.45 - 21.98
Open 13.71
Vol / Avg. 950,562.00/2.28M
Mkt cap 2.24B
P/E     -
Div/yield     -
EPS -3.04
Shares 163.89M
Beta 1.32
Inst. own 95%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -23.55% -17.00%
Operating margin -9.48% -15.00%
EBITD margin - 14.34%
Return on average assets -6.15% -4.54%
Return on average equity -25.30% -12.95%
Employees 980 -
CDP Score - -

Address

Dublin 4 1st Fl 1 Burlington Road, Connaught House
DUBLIN, HM 09
Ireland
+353-1-7722100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

Officers and directors

Timothy P. Walbert Chairman of the Board, President, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Paul W. Hoelscher Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Barry J. Moze Executive Vice President, Chief Administrative Officer
Age: 63
Bio & Compensation  - Reuters
Brian K. Beeler Executive Vice President, General Counsel
Age: 44
Bio & Compensation  - Reuters
Robert F. Carey Executive Vice President, Chief Business Officer
Age: 58
Bio & Compensation  - Reuters
Michael A. DesJardin Executive Vice President - Technical Operations
Age: 59
Bio & Compensation  - Reuters
George P. Hampton Executive Vice President - Primary Care Business Unit
Age: 47
Bio & Compensation  - Reuters
David A. Happel Executive Vice President - Orphan Business Unit
Age: 54
Bio & Compensation  - Reuters
Jeffrey W. Sherman M.D. Executive Vice President - Research and Development and Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Vikram Karnani Senior Vice President - Rheumatology Business Unit
Age: 42
Bio & Compensation  - Reuters